Efficacy of lanreotide Autogel® administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial

Authors:
  • TAthe Spanish–Portuguese Multicentre Autogel Study Group on Acromegaly
    the Spanish–Portuguese Multicentre Autogel Study Group on Acromegaly
Publisher website
Google Scholar
Abstract
Summary: Objective and design  Depot somatostatin analogues are well accepted as either adjuvant or primary therapy for acromegaly, and their long dosage intervals facilitate adherence to treatment. Our objective was to evaluate whether lanreotide Autogel® 120 mg, every 4–8 weeks, was as effective in controlling acromegaly as lanreotide microparticles 30 mg, every 1–2 weeks.Patients design and measurements  Patients who had used lanreotide microparticles 30 mg, ≥ 2 months prestudy, and had responded to treatment were recruited to this open, prospective, multicentre phase III trial. Three to five injections of lanreotide Autogel® 120 mg were administered. Lanreotide Autogel® 120 mg was injected every 4, 6 or 8 weeks in patients previously receiving lanreotide microparticles every 7, 10 or 14 days, respectively. GH and insulin‐like growth factor (IGF)‐1 levels were assessed one dosing interval after the final injections.Results  Ninety‐eight patients were enrolled and 93 completed. Steady‐state GH concentrations demonstrated similar efficacy between the formulations (upper 95% confidence interval of the quotient, 77·7%). Mean (SE) GH levels were lower with lanreotide Autogel® than with lanreotide microparticles (3·8 (0·5) vs 4·3 (0·5) ng/ml; P < 0·001). GH levels < 2·5 ng/ml were observed in 54% and 46% of patients; 40% and 35% having GH < 2·5 ng/ml and normalized IGF‐1 with lanreotide Autogel® and microparticles, respectively. Symptoms were controlled better with lanreotide Autogel® and treatment was well accepted.Conclusions  Lanreotide Autogel® 120 mg every 4–8 weeks, is at least as effective and as well tolerated in acromegaly as lanreotide microparticles 30 mg injected every 7–14 days.

This publication has 39 references indexed in Scilit: